Literature DB >> 31814979

MicroRNA-429 inhibits cancer cell proliferation and migration by targeting AKT1 in renal cell carcinoma.

Zhengming Su1,2, Ganggang Jiang1,3, Jinlan Chen1, Xing Liu1, Haibo Zhao1, Zhiyuan Fang3, Yongzhong He1, Xianhan Jiang1,2, Guibin Xu1,2.   

Abstract

MicroRNAs (miRNAs or miR) serve as oncogenes and tumor suppressors. In a previous study, it was revealed that has-miRNA-429 (miR-429) is a tumor suppressor in 786-O renal cell carcinoma (RCC) cells. However, its mechanism in RCC remains to be determined. The present study aimed to explain the functional role and mechanism of miR-429 in RCC pathogenesis. Luciferase reporter assays demonstrated that miR-429 overexpression reduced the transcriptional activity of AKT serine/threonine kinase 1 (AKT1). Reverse transcripton-quantitative (RT-q) PCR and western blot analysis indicated that the mRNA and protein expression of AKT1 was downregulated in 786-O RCC cell lines when miR-429 was overexpressed, indicating that miR-429 may directly target AKT1 in RCC. Therefore, miR-429 overexpression enhanced the inhibition of tumor size and weight in nude mice in vivo. The current study indicated that the novel miR-429-regulated pathway may provide insights into RCC oncogenesis and metastasis.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  AKT serine/threonine kinase 1; microRNA-429; renal cell carcinoma

Year:  2019        PMID: 31814979      PMCID: PMC6888107          DOI: 10.3892/mco.2019.1940

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  36 in total

1.  MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial-mesenchymal transition.

Authors:  Jing Tang; Liang Li; Wentao Huang; Chengjun Sui; Yingcheng Yang; Ximeng Lin; Guojun Hou; Xin Chen; Jing Fu; Shengxian Yuan; Shao Li; Wen Wen; Shanhua Tang; Dan Cao; Mengchao Wu; Lei Chen; Hongyang Wang
Journal:  Cancer Lett       Date:  2015-04-27       Impact factor: 8.679

2.  miR-429 modulates the expression of c-myc in human gastric carcinoma cells.

Authors:  Tiewei Sun; Chunmei Wang; Jun Xing; Dequan Wu
Journal:  Eur J Cancer       Date:  2011-06-16       Impact factor: 9.162

Review 3.  MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects.

Authors:  Jinglei Miao; Song Wu; Zhi Peng; Mousumi Tania; Chaoyue Zhang
Journal:  Tumour Biol       Date:  2013-08

4.  MicroRNA-137 chemosensitizes colon cancer cells to the chemotherapeutic drug oxaliplatin (OXA) by targeting YBX1.

Authors:  Yunsheng Guo; Yan Pang; Xia Gao; Min Zhao; Xin Zhang; Hao Zhang; Bing Xuan; Yimin Wang
Journal:  Cancer Biomark       Date:  2017       Impact factor: 4.388

5.  Downregulation of microRNA-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells.

Authors:  Yongri Ouyang; Ping Gao; Baoyi Zhu; Xi Chen; Fang Lin; Xi Wang; Junxia Wei; Huizhong Zhang
Journal:  Mol Med Rep       Date:  2014-10-27       Impact factor: 2.952

6.  MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4.

Authors:  Gang Yu; Benli Jia; Yunsheng Cheng; Lianbang Zhou; Bo Qian; Zhining Liu; Yong Wang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 7.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  MicroRNA-184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation.

Authors:  Chong-Zhen Qin; Xiao-Ya Lou; Qiao-Li Lv; Lin Cheng; Na-Yiyuan Wu; Lei Hu; Hong-Hao Zhou
Journal:  Pharmazie       Date:  2015-10       Impact factor: 1.267

9.  Akt: a double-edged sword in cell proliferation and genome stability.

Authors:  Naihan Xu; Yuanzhi Lao; Yaou Zhang; David A Gillespie
Journal:  J Oncol       Date:  2012-03-15       Impact factor: 4.375

10.  High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.

Authors:  Can Wei; Song Wu; Xianxin Li; Yadong Wang; Rui Ren; Yongqing Lai; Jiongxian Ye
Journal:  Oncol Lett       Date:  2012-11-16       Impact factor: 2.967

View more
  6 in total

1.  Correlation between Structural Transformations in Mesenteric Lymph Nodes and the Levels MicroRNA during Polychemotherapy of Breast Cancer.

Authors:  A V Kabakov; O V Kazakov; A F Poveshchenko; A P Lykov; T V Raiter; D N Strunkin; L F Gulyaeva; V I Konenkov; A Yu Letyagin
Journal:  Bull Exp Biol Med       Date:  2022-02-17       Impact factor: 0.804

2.  Silencing miR-454 suppresses cell proliferation, migration and invasion via directly targeting MECP2 in renal cell carcinoma.

Authors:  Huan Liu; Qun-Long Liu; Ting-Shuai Zhai; Jun Lu; Yun-Ze Dong; Yun-Fei Xu
Journal:  Am J Transl Res       Date:  2020-08-15       Impact factor: 4.060

3.  MiR-27b-3p inhibits the progression of renal fibrosis via suppressing STAT1.

Authors:  Lin Bai; Yongtao Lin; Juan Xie; Yiyuan Zhang; Hongwu Wang; Donghui Zheng
Journal:  Hum Cell       Date:  2021-01-17       Impact factor: 4.174

Review 4.  The role of miR-200 family in the regulation of hallmarks of cancer.

Authors:  Klaudia Klicka; Tomasz M Grzywa; Aleksandra Mielniczuk; Alicja Klinke; Paweł K Włodarski
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

5.  CircCSNK1G3 up-regulates miR-181b to promote growth and metastasis via TIMP3-mediated epithelial to mesenchymal transitions in renal cell carcinoma.

Authors:  Wen Li; Yang-Yi-Yan Song; Ting Rao; Wei-Min Yu; Yuan Ruan; Jin-Zhuo Ning; Xiao-Bing Yao; Song-Yi-Sha Yang; Fan Cheng
Journal:  J Cell Mol Med       Date:  2021-02-09       Impact factor: 5.295

6.  Circular RNA circRNA_0082835 promotes progression and lymphatic metastasis of primary melanoma by sponging microRNA miRNA-429.

Authors:  Yute Sun; Zuoqiong Hou; Binlin Luo; Chujun Li; Jinfang Liu; Jianlan Liu; Jian Tang; Gang Yao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.